HEMO vs. ONC, SBTX, OBD, C4XD, DEST, OPTI, OBI, NSCI, SNG, and SAR
Should you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include Oncimmune (ONC), SkinBioTherapeutics (SBTX), Oxford BioDynamics (OBD), C4X Discovery (C4XD), Destiny Pharma (DEST), OptiBiotix Health (OPTI), Ondine Biomedical (OBI), NetScientific (NSCI), Synairgen (SNG), and Sareum (SAR). These companies are all part of the "biotechnology" industry.
Hemogenyx Pharmaceuticals (LON:HEMO) and Oncimmune (LON:ONC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, valuation and community ranking.
Oncimmune has higher revenue and earnings than Hemogenyx Pharmaceuticals. Oncimmune is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oncimmune's average media sentiment score of 0.46 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that Oncimmune is being referred to more favorably in the news media.
Hemogenyx Pharmaceuticals has a beta of 3.06, meaning that its share price is 206% more volatile than the S&P 500. Comparatively, Oncimmune has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
Oncimmune received 13 more outperform votes than Hemogenyx Pharmaceuticals when rated by MarketBeat users. Likewise, 59.13% of users gave Oncimmune an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote.
Oncimmune has a net margin of 356.25% compared to Hemogenyx Pharmaceuticals' net margin of 0.00%. Hemogenyx Pharmaceuticals' return on equity of -136.44% beat Oncimmune's return on equity.
0.8% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 35.5% of Oncimmune shares are held by institutional investors. 11.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Comparatively, 28.8% of Oncimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Oncimmune beats Hemogenyx Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
Get Hemogenyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HEMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hemogenyx Pharmaceuticals Competitors List
Related Companies and Tools
